Background:
Carboplatin and paclitaxel (CP) has been the standard treatment for platinum-sensitive recurrent ovarian cancer. Leukopenia and sensory neuropathy are common toxicities of CP. We assess the prognostic value of these toxicities and whether they predict CP...(more) |